A Phase 3 interventional study of Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML), sponsored by AbbVie. Active, not recruiting at 172 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.
Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 10th largest by enrollment, is one of 7 that started in 2017, is one of 16 in phase 3, reaches primary completion later than 0 of the 143 other live ones, and was the 9th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18–59
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 60+
Virginia Commonwealth University · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 127 · Phase 3 26 · Phase 4 5
First in 2010; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 443 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 57 across the 202 interventional studies. Of the 46 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 202 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
43 studies in Leukemia, Myeloid, Acute by AbbVie: 4 open now, 10 under way, 3 of them phase 3. Of 31 finished, 7 (23%) have results posted.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 3rd largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2017, is one of 7 in phase 3, and was the 10th registered.
AbbVie’s Leukemia, Myeloid, Acute studies by the year they started, since 2010.
38 of the studies testing venetoclax in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07264010Phase 3Nanfang Hospital, Southern Medical UniversitySorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | 2026-12-30 |
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
Add all 38 to your calendar (.ics) → With an account.
Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, from their registry updates:
Among AbbVie’s 43 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the participant has, and the age of the participant when diagnosed.
Venetoclax is an experimental drug that kills cancer cells by blocking a protein (part of a cell) that allows cancer cells to stay alive. This study is designed to see if adding venetoclax to azacitidine works better than azacitidine on its own.
This is a Phase 3, randomized, double-blind (treatment is unknown to participants and doctors), placebo controlled study in patients with AML who are >= 18 or more years old and have not been treated before. Participants who take part in this study should not be suitable for standard induction therapy (usual starting treatment). AbbVie is funding this study which will take place at approximately 180 hospitals globally and enroll approximately 400 participants.
In this study, 2/3 of participants will receive venetoclax every day with azacitidine and the remaining 1/3 will receive placebo (dummy) tablets with azacitidine.
Participants will continue to have study visits and receive treatment for as long as they are having a clinical benefit. The effect of the treatment on AML will be checked by taking blood, bone marrow, scans, measuring side effects and by completing health questionnaires. Blood and bone marrow tests will be completed to see why some people respond better than others. Additional blood tests will be completed for genetic factors and to see how long the drug remains in the body.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant must be considered ineligible for induction therapy defined by the following:
a. >= 75 years of age; or b. >= 18 to 74 years of age with at least one of the following comorbidities: i. (ECOG) Performance Status of 2 or 3; ii. Cardiac history of Congestive Heart Failure (CHF) requiring treatment or \<= 50% or chronic stable angina; iii. Diffusing capacity of the Lung for Carbon Monoxide (DLCO) \<= 65% or (FEV1) \<= 65%; iv. >= 30 mL/min to \< 45 ml/min; v. Moderate hepatic impairment with total > 1.5 to \<= 3.0 × (ULN); vi. Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the AbbVie Therapeutic Medical Director during screening and before study enrollment.
Participant must have an ECOG Performance status:
Participant must have adequate liver function as demonstrated by:
i. Participants who are \< 75 years of age may have a bilirubin of \<= 3.0 x ULN
Female participants must be either defined as:
Female participants of childbearing potential must have negative results for pregnancy test performed:
Exclusion Criteria:
Participant has received treatment with the following:
Participant has the following:
a. Favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per the National Comprehensive Cancer Network (NCCN) Guidelines Version 2, 2016 for Acute Myeloid Leukemia.
Participant has a history of other within 2 years prior to study entry, with the exception of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolled under original protocol and enrolled during or after protocol amendment 1 received venetoclax-matching placebo, orally, every day (QD), from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\^2, subcutaneously (SC) or intravenously (IV), QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
Drug: Azacitidine · Drug: Placebo
Participants enrolled under original protocol and enrolled during or after protocol amendment 1 received venetoclax 100 mg, once orally, on Day 1 of Cycle 1 followed by venetoclax 200 mg, once orally, on Day 2 of Cycle 1 and venetoclax 400 mg, orally, QD, on Day 3 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\^2, SC or IV, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
Drug: Azacitidine · Drug: Venetoclax
Participants received venetoclax 400 mg, orally, QD, from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\^2, SC, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
Drug: Azacitidine · Drug: Venetoclax
Solution for subcutaneous or intravenous administration.
Tablet
Also known as: ABT-199
Matching placebo tablet
Overall Survival (OS)
OS is defined as the number of days from the date of randomization to the date of death. Log rank test was used to compare the OS distribution between two treatment arms. Cox regression was used to report the hazard ratio.
Time frame: From the study start up to death or alive or lost to follow-up (up to approximately 4.8 years; data cut off date: 1 December 2021)
Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Marrow Recovery (CRi)
CR and CRi was calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count \>10\^3/ microliter (mcL), platelets \>10\^5/mcL, red cell transfusion independence, and bone marrow with \<5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of ≤10\^3/mcL or platelets ≤10\^5/mcL. Percentages are rounded off to whole number at the nearest decimal.
Time frame: From the study start up to death (up to approximately 4.8 years; data cut-off date: 1 December 2021)
Event-free Survival (EFS)
EFS will be defined as the number of days from randomization to the date of progressive disease, relapse from CR or CRi, treatment failure or death from any cause.
Time frame: Measured up to 2 years after the last participant is randomized
Global Health Status/Quality of Life (GHS/QoL)
Improvement in GHS/QoL will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30).
Time frame: Measured at participant's Day 1 of Cycle 1 (each cycle is 28 days) and at Day 1 of every Cycle thereafter for up to 2 years following the last subject last visit
Percentage of Participants Achieving Composite Complete Remission (CR or CRi)
This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count \> 10\^3/mcL, platelets \> 10\^5/mcL, red cell transfusion independence, and bone marrow with \< 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of \<= 10\^3/mcL or platelets \<= 10\^5/mcL.
Time frame: Up to 6 months after the first 225 participants are randomized
Complete Remission or Complete Remission With Partial Hematologic Recovery Rate (CR+CRh)
A response of CRh is defined as Bone marrow with \<5% blasts, peripheral blood neutrophil count \>0.5\*10\^3/mcL and peripheral blood platelet count \>0.5\*10\^5/mcL.
Time frame: Measured up to 2 years after the last participant is randomized
Post Baseline Transfusion Independence Rate
Transfusion Independence is defined as a period of 56 days with no transfusion between first dose of study drug and the last dose of study drug + 30 days. The rate of conversion for red blood cells (RBC) and platelets is defined as percentage of participants being post-baseline transfusion independent from baseline transfusion dependence.
Time frame: Measured up to 2 years after the last participant is randomized
Complete Remission (CR) Rate
The percentage of participants with complete remission (CR) will be calculated based on the modified IWG criteria for AML.
Time frame: Measured up to 2 years after the last participant is randomized
Fatigue/Quality of Life (QoL)
Fatigue QoL will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Fatigue Short Form (SF) 7a global fatigue score
Time frame: Measured at participant's Day 1 of Cycle 1 (each cycle is 28 days) and at Day 1 of every Cycle thereafter for up to 2 years following the last participant last visit
Participants were randomized in Group 1 per original protocol stratified by age (18 - \< 75, ≥ 75), and region (US, EU, Japan (JP), Rest of world (ROW)) and Group 2 during or after Amendment 1 stratified by age (18 - \< 75, ≥ 75), cytogenetic risk (intermediate, poor) and region (US, EU, China, JP, ROW).
| Milestone | Group 1: Placebo + Azacitidine 75 mg/m^2 | Group 1: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | Group 2: Placebo + Azacitidine 75 mg/m^2 | Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2 |
|---|---|---|---|---|---|
| Started | 1 | 1 | 145 | 286 | 10 |
| Completed | 0 | 0 | 1 | 48 | 4 |
| Not completed | 1 | 1 | 144 | 238 | 6 |
| Withdrew: Withdrew consent | 0 | 0 | 2 | 9 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 6 | 0 |
| Withdrew: Death | 1 | 1 | 138 | 222 | 6 |
| Withdrew: Reason not specified | 0 | 0 | 1 | 1 | 0 |
OS is defined as the number of days from the date of randomization to the date of death. Log rank test was used to compare the OS distribution between two treatment arms. Cox regression was used to report the hazard ratio.
| months | Group 2: Placebo + Azacitidine 75 mg/m^2 | Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 |
|---|---|---|
| Overall Survival (OS) | 9.6 (7.4 to 12.7) | 14.7 (12.1 to 18.7) |
CR and CRi was calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count \>10\^3/ microliter (mcL), platelets \>10\^5/mcL, red cell transfusion independence, and bone marrow with \<5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of ≤10\^3/mcL or platelets ≤10\^5/mcL. Percentages are rounded off to whole number at the nearest decimal.
| percentage of participants | Group 2: Placebo + Azacitidine 75 mg/m^2 | Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2 |
|---|---|---|---|
| CR | 17.9 (12.1 to 25.2) | 38.8 (33.1 to 44.7) | 60.0 (26.2 to 87.8) |
| CRi | 11.0 (6.4 to 17.3) | 28.0 (22.8 to 33.6) | 20.0 (2.5 to 55.6) |
EFS will be defined as the number of days from randomization to the date of progressive disease, relapse from CR or CRi, treatment failure or death from any cause.
Results for this outcome have not been posted.
Improvement in GHS/QoL will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30).
Results for this outcome have not been posted.
This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count \> 10\^3/mcL, platelets \> 10\^5/mcL, red cell transfusion independence, and bone marrow with \< 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of \<= 10\^3/mcL or platelets \<= 10\^5/mcL.
Results for this outcome have not been posted.
A response of CRh is defined as Bone marrow with \<5% blasts, peripheral blood neutrophil count \>0.5\*10\^3/mcL and peripheral blood platelet count \>0.5\*10\^5/mcL.
Results for this outcome have not been posted.
Transfusion Independence is defined as a period of 56 days with no transfusion between first dose of study drug and the last dose of study drug + 30 days. The rate of conversion for red blood cells (RBC) and platelets is defined as percentage of participants being post-baseline transfusion independent from baseline transfusion dependence.
Results for this outcome have not been posted.
The percentage of participants with complete remission (CR) will be calculated based on the modified IWG criteria for AML.
Results for this outcome have not been posted.
Fatigue QoL will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Fatigue Short Form (SF) 7a global fatigue score
Results for this outcome have not been posted.
Collected over From the study start until data cut-off date: 01 December 2021 (up to approximately 4.8 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 and Group 2: Placebo + Azacitidine 75 mg/m^2 | 140/144 (97.2%) | 111/144 (77.1%) | 137/144 (95.1%) |
| Group 1 and Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | 226/283 (79.9%) | 242/283 (85.5%) | 279/283 (98.6%) |
| Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2 | 6/10 (60%) | 7/10 (70%) | 10/10 (100%) |
| Event | Group 1 and Group 2: Placebo + Azacitidine 75 mg/m^2 | Group 1 and Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2 |
|---|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 15/144 | 88/283 | 2/10 |
| NEUTROPENIABlood and lymphatic system disorders | 4/144 | 14/283 | 3/10 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 3/144 | 14/283 | 3/10 |
| PNEUMONIAInfections and infestations | 35/144 | 55/283 | 0/10 |
| LUNG INFECTIONInfections and infestations | 3/144 | 10/283 | 2/10 |
| CARDIAC FAILURECardiac disorders | 3/144 | 7/283 | 1/10 |
| VERTIGOEar and labyrinth disorders | 0/144 | 1/283 | 1/10 |
| PANCREATITIS ACUTEGastrointestinal disorders | 0/144 | 0/283 | 1/10 |
| PSEUDOMONAL SEPSISInfections and infestations | 2/144 | 2/283 | 1/10 |
| HYPOXIARespiratory, thoracic and mediastinal disorders | 1/144 | 0/283 | 1/10 |
| Event | Group 1 and Group 2: Placebo + Azacitidine 75 mg/m^2 | Group 1 and Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2 |
|---|---|---|---|
| LEUKOPENIABlood and lymphatic system disorders | 20/144 | 54/283 | 10/10 |
| HYPOKALAEMIAMetabolism and nutrition disorders | 43/144 | 84/283 | 8/10 |
| CONSTIPATIONGastrointestinal disorders | 55/144 | 121/283 | 7/10 |
| ANAEMIABlood and lymphatic system disorders | 24/144 | 68/283 | 6/10 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 57/144 | 120/283 | 6/10 |
| DECREASED APPETITEMetabolism and nutrition disorders | 26/144 | 78/283 | 6/10 |
| NEUTROPENIABlood and lymphatic system disorders | 38/144 | 107/283 | 5/10 |
| DIARRHOEAGastrointestinal disorders | 46/144 | 122/283 | 5/10 |
| VOMITINGGastrointestinal disorders | 33/144 | 84/283 | 5/10 |
| HYPOCALCAEMIAMetabolism and nutrition disorders | 9/144 | 19/283 | 5/10 |
Full Analysis Set included all Group 1 and 2 participants randomized by Interactive Voice Response System (IVRS)/Interactive Web Response System (IWRS) (exclude the open-label China safety cohort). Open-Label China Safety Cohort included participants who received at least one dose of venetoclax.
| Age, Continuous(years) | Group 1: Placebo + Azacitidine 75 mg/m^2 | Group 1: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | Group 2: Placebo + Azacitidine 75 mg/m^2 | Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|---|---|---|
| Mean | 61.0 ± NA | 65.0 ± NA | 75.1 ± 5.70 | 75.6 ± 6.08 | 70.2 ± 7.44 | 75.2 ± 6.08 |
| Sex: Female, Male(Participants) | Group 1: Placebo + Azacitidine 75 mg/m^2 | Group 1: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | Group 2: Placebo + Azacitidine 75 mg/m^2 | Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 0 | 58 | 114 | 4 | 177 |
| Male | 0 | 1 | 87 | 172 | 6 | 266 |
| Race (NIH/OMB)(Participants) | Group 1: Placebo + Azacitidine 75 mg/m^2 | Group 1: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | Group 2: Placebo + Azacitidine 75 mg/m^2 | Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 | Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 33 | 66 | 10 | 109 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 2 | 3 | 0 | 6 |
| White | 0 | 1 | 109 | 217 | 0 | 327 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
Showing the first 100 of 172 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Feb 2017 to primary completion in Dec 2021, 57 months.
Results were first posted in Jan 2023, 1 year 1 month after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 57 months is above that.
Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venetoclax